PriceTargets.com logo

Gain Therapeutics - GANX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.25
  • Forecasted Upside: 364.74%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$1.56 As of 12/20/2024 06:31 PM ET
▼ -0.01 (-0.64%)

This chart shows the closing price for GANX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gain Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GANX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GANX

Analyst Price Target is $7.25
▲ +364.74% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Gain Therapeutics in the last 3 months. The average price target is $7.25, with a high forecast of $8.00 and a low forecast of $6.00. The average price target represents a 364.74% upside from the last price of $1.56.

This chart shows the closing price for GANX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Gain Therapeutics. This rating has held steady since July 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/6/2024Roth MkmInitiated CoverageBuy$7.00
12/5/2024Roth CapitalUpgradeStrong-Buy
11/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
10/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
10/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
8/14/2024OppenheimerReiterated RatingOutperform$8.00
8/9/2024Chardan CapitalReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
7/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
7/2/2024HC WainwrightLower TargetBuy ➝ Buy$9.00 ➝ $8.00
5/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00
4/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00
4/23/2024OppenheimerReiterated RatingOutperform ➝ Outperform$9.00
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00
3/27/2024Chardan CapitalReiterated RatingBuy ➝ Buy$6.00
12/4/2023HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $9.00
9/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00
9/12/2023Maxim GroupInitiated CoverageBuy$10.00
8/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00
8/14/2023Chardan CapitalReiterated RatingBuy ➝ Buy$6.00
3/27/2023Chardan CapitalBoost Target$4.00 ➝ $5.75
12/9/2022Chardan CapitalInitiated CoverageBuy$4.00
11/25/2022OppenheimerLower TargetOutperform$30.00 ➝ $10.00
11/14/2022HC WainwrightLower TargetBuy$12.00 ➝ $10.00
11/13/2022BTIG ResearchLower TargetBuy$30.00 ➝ $10.00
8/19/2022B. RileyDowngradeBuy ➝ Neutral$11.00 ➝ $5.00
5/23/2022B. RileyLower Target$16.00 ➝ $11.00
3/29/2022B. RileyLower TargetBuy$21.00 ➝ $16.00
3/29/2022HC WainwrightInitiated CoverageBuy$12.00
11/12/2021OppenheimerReiterated RatingOutperform$30.00
11/3/2021B. RileyInitiated CoverageBuy$21.00
4/12/2021BTIG ResearchInitiated CoverageBuy$30.00
4/12/2021OppenheimerInitiated CoverageOutperform$30.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.99 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Gain Therapeutics logo
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
Read More

Today's Range

Now: $1.56
Low: $1.50
High: $1.70

50 Day Range

MA: $2.05
Low: $1.54
High: $2.92

52 Week Range

Now: $1.56
Low: $0.89
High: $5.33

Volume

150,258 shs

Average Volume

263,818 shs

Market Capitalization

$41.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Gain Therapeutics?

The following sell-side analysts have issued reports on Gain Therapeutics in the last year: Chardan Capital, HC Wainwright, Oppenheimer Holdings Inc., Roth Capital, and Roth Mkm.
View the latest analyst ratings for GANX.

What is the current price target for Gain Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Gain Therapeutics in the last year. Their average twelve-month price target is $7.25, suggesting a possible upside of 364.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting GANX will reach $8.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $6.00 for Gain Therapeutics in the next year.
View the latest price targets for GANX.

What is the current consensus analyst rating for Gain Therapeutics?

Gain Therapeutics currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GANX will outperform the market and that investors should add to their positions of Gain Therapeutics.
View the latest ratings for GANX.

What other companies compete with Gain Therapeutics?

Other companies that are similar to Gain Therapeutics include TuHURA Biosciences, Bright Minds Biosciences, Corbus Pharmaceuticals, Actuate Therapeutics and Sagimet Biosciences. Learn More about companies similar to Gain Therapeutics.

How do I contact Gain Therapeutics' investor relations team?

Gain Therapeutics' physical mailing address is 4800 HAMPDEN LANE SUITE 200, BETHESDA MD, 20814. The company's listed phone number is 301-500-1556 and its investor relations email address is [email protected]. The official website for Gain Therapeutics is www.gaintherapeutics.com. Learn More about contacing Gain Therapeutics investor relations.